In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Dublin, Aug. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Oncolytic virus (OV)-based immunotherapy has ... augmenting the immune response against cancer. The success of OV therapy is ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

Replimune's cash runway supports its accelerated approval and phase 3 trial. See why I think REPL's current low stock price ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

Vibration therapy is a rehabilitation method that uses mechanical oscillations or vibrations to stimulate the body. Research suggests it may improve posture, increase range of motion, promote ...

The global cancer gene therapy market is set for significant expansion, with projections indicating a robust compound annual ...

Labroots and the Cell & Gene Therapy planning committee are thrilled to announce the debut of the Cell & Gene Therapy Virtual Event Series, premiering exclisively online October 16th, 2024. Join us as ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...